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Abstract:  The BCR/ABL fusion protein is the hallmark of Philadelphia Chromosome positive (Ph+) leukemia. The   
constitutive activation of the ABL-kinase in BCR/ABL cells induces the leukemic phenotype. Targeted inhibition of 
BCR/ABL by small molecule inhibitors reverses the transformation potential of BCR/ABL. Recently, we definitively 
proved that targeting the tetramerization of BCR/ABL mediated by the N-terminal coiled-coil domain (CC) using com-
petitive peptides, representing the helix-2 of the CC, represents a valid therapeutic approach for treating Ph+ leukemia.  
To further develop competitive peptides for targeting BCR/ABL, we created a membrane permeable helix-2 peptide 
(MPH-2) by fusing the helix-2 peptide with a peptide transduction tag. In this study, we report that the MPH-2:   
(i) interacted with BCR/ABL in vivo; (ii) efficiently inhibited the autophosphorylation of BCR/ABL; (iii) suppressed  
the growth and viability of Ph+ leukemic cells; and (iv) was efficiently transduced into mononuclear cells (MNC) in an  
in vivo mouse model. 
This study provides the first evidence that an efficient peptide transduction system facilitates the employment of   
competitive peptides to target the oligomerization interface of BCR/ABL in vivo. 
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INTRODUCTION 
  The BCR/ABL fusion protein is the hallmark of Phila-
delphia chromosome-positive (Ph+) leukemia. BCR/ABL is 
characterized by deregulated and constitutively activated 
ABL tyrosine kinase (TK), which determines its transforma-
tion potential [1]. Cellular transformation and leukemogene-
sis are strictly dependent on the TK activity of BCR/ABL [2-
5]. Molecular-targeted therapy with selective ABL-kinase 
inhibitors (AKI) such as Imatinib, Dasatinib, or Nilotinib 
induces complete hematological and cytogenetic remission 
in the majority of Ph+ leukemia patients [6]. However, in 
advanced stage disease, relapse frequently occurs, and is 
accompanied by resistance to further treatment with kinase 
inhibitors. In the majority of the cases, the development of 
resistance is due to clones harboring point mutations in the 
ABL portion of the fusion protein that interfere with the 
binding of the inhibitors, and these clones are selected with 
continuous exposure to AKIs [7, 8]. 
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  Tetramerization of ABL through the N-terminal coiled-
coil region (CC) of BCR is essential for aberrant ABL-
kinase activation [9, 10]. 
  The CC contains the helix alpha 1 (a.a. 5-15) and alpha 2 
(a.a. 28-67), which are separated by a flexible loop. The di-
mer interface is formed by the direct interaction of the heli-
ces-2 of each monomer, while the helix-1 from one mono-
mer swings back and packs against the ‘‘outside’’ of the he-
lix-2 dimer, and interacts with the helix-2 of the other 
monomer [11]. Deletion of the helix-2 impairs oligomeriza-
tion and reduces kinase activity [12]. Recently, we have 
shown that targeting the CC-domain forces BCR/ABL into a 
monomeric conformation, which abolishes its transformation 
potential by interfering with its kinase activity. This also 
increases the sensitivity of the leukemic cells to Imatinib   
[9, 13]. 
  Peptide-based molecular targeting is emerging as an   
important therapeutic approach for treating human cancers 
[14]. The obvious limitations of using peptides as therapeu-
tics are poor permeability and low selectivity. A potential 
strategy to overcome these limitations is the peptide trans-
duction (PT) system, which involves conjugating the peptide 
of interest to a protein transduction domain (PTD), confer-
ring the capacity to pass through the cell membrane of living 22    The Open Hematology Journal, 2011, Volume 5  Mian et al. 
cells [15]. All of the different PTDs that have been identified 
contain stretches of 9-11 a.a., which are usually basic and 
predominantly consist of arginine residues [16]. The effi-
ciency of the receptor-independent uptake mediated by the 
different PTDs varies with the conjugated peptides and target 
cells [17]. An example of a PTD is HIV-TAT, which is de-
rived from the human immunodeficiency viral protein TAT, 
and contains an arginine-rich sequence of 11 a.a. [18, 19]. 
Rapid receptor-independent uptake of TAT-conjugated   
peptides occurs in many cell types and animals [17, 20, 21]. 
  The aim of this study was to develop a novel cell based 
in vivo delivery system. The results generated from this 
study may significantly contribute to the advancement of the 
field of cell and peptide based therapeutics to treat Imatinib-
resistant Ph+ leukemia. 
MATERIAL AND METHODOLOGY 
Plasmids 
  All expression vectors used in this study were based on 
pPRIBA2, which provides an in-frame Strep Tag as well as a 
His-tag (IBA - BioTAGnology, Göttingen, Germany). 
pPRIBA2 was converted into a Gateway®-destination vector 
by the introduction of a Gateway® cassette, according to the 
manufacturer’s instructions (Invitrogen, Karlsruhe, Ger-
many). All related inserts were available in the Gateway® 
entry-vector (pENTR1A), and were shuttled into the destina-
tion vectors using the “LR-clonase” enzyme kit (Invitrogen). 
The pENTR1A with GFP and the helix-2-GFP fusion pep-
tide (pE-GFP and pE-H2-GFP, respectively) have been   
previously described [13]. For the generation of the HIV-
TAT-H2GFP fusion peptides (here referred to as MPH-2), 
the following linkers were used 5‘- gcgcctacggccgcaagaag-
cgacgtcagagacgacgcgtcaac-3‘ and 5‘- tatcgttgacgcgtcgtctct- 
gacgtcgcttcttgcggccgtag-3‘. Retro-HIV-TAT-H2GFP fusion 
peptides were generated using the linkers 5‘- gcgcccgaagac- 
gccaacgaaggaagaaacgggtcaac-3‘ and 5‘-tatcgttgacccgtttctt- 
ccttcgttggcgtcttcgg -3‘. The resulting PCR products were   
all confirmed by sequencing, and were cloned into the 
pPRIBA2 vector using a BsaI site, and recombined with pE-
GFP and pE-H2GFP. The pPRIBA2-GFP and pPRIBA2-H2-
GFP vectors were constructed by directly shuttling pE-GFP 
and pE-H2GFP into the pRIBA2 vector. 
CELL LINES  
  Nalm-6, BV-173, K562 and Tom-1 cells were obtained 
from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). Nalm-6, BV-
173, K562 were maintained in RPMI 1640 medium supple-
mented with 10% fetal calf serum (FCS), and Tom-1 was 
maintained in 20% FCS (Invitrogen, Karlsruhe, Germany). 
Rat-1 and 293T cells were cultured in DMEM supplemented 
with 10% FCS. Cell growth was assessed by Trypan-blue 
dye exclusion. Proliferation was assessed with the XTT pro-
liferation kit (Roche, Mannheim, Germany) according to the 
manufacturer’s instructions. 
PRODUCTION OF RECOMBINANT TAT- FUSION 
PROTEINS 
  The strep-tagged H2-GFP, TAT-GFP and MPH-2 pep-
tides were produced in E.coli BL21 from pPRIBA2 vectors 
upon induction with 0.5 mM isopropyl thiogalactoside 
(IPTG) overnight at 25°C. Bacterial lysates were prepared in 
buffer W (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 0.1% Tween) containing a complete protease inhibi-
tor cocktail (Roche Basel Switzerland), sonicated, and 
cleared by centrifugation (10.000 g for 10 min.). Further 
purification of the STREP-tagged peptides was performed 
using a STREPtactin Matrix (IBA - BioTAGnology). The 
beads were washed 4 times with buffer W, and the proteins 
were eluted with elution buffer at room temperature for 15 
min. The buffer was exchanged with PBS using PD-10 col-
umns (Amersham/Pharmacia Biotec, Freiburg, Germany), 
and the endotoxin was removed using endotoxin free col-
umns (Profos AG, Regensburg, Germany). The amount of 
protein was quantified by comparing the samples to a bovine 
serum albumin (BSA) standard curve. Samples were stored 
at -20°C
 in 15-20% glycerol for further use. Quantification 
of proteins was performed using SDS-PAGE followed by 
coomassie-staining. 
DETERMINATION OF TAT-FUSION PROTEIN   
UPTAKE  
  To determine the uptake efficiency of the fusion proteins, 
1x 10
5 cells/well of 293T, Rat-1, Nalm-6, BV-173, K562 and 
Tom-1 were plated in a 12-well plate for 12-16 hr. Cells 
were then incubated with H2-GFP, TAT-GFP or MPH-2 (1 
μM each) for 3 hr. The cells were washed with PBS, har-
vested, and the uptake efficiency was measured by quantifi-
cation of the GFP-positivity by fluorescent activated cell 
sorting (FACS). 
WESTERN BLOT 
  Western blot analyses were performed according to 
widely established protocols. Lysates were obtained using 
E1A buffer – 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 50 
mM HEPES, 0.1% NP40 and protease-inhibitors (Roche 
Basel, Switzerland) to separate the soluble cytoplasmic   
fraction from the membrane-associated (NP-40 insoluble 
fraction). The following antibodies were used: anti-ABL   
(-ABL) (St. Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-phosphorylated ABL specific for the phosphorylated 
tyrosine-residue 245 (-p-ABL-Tyr-245) (Upstate-Bio- 
technology, Lake Placid, NY, USA), anti-GFP (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Blocking and anti-
body incubation steps were performed in 5% low fat dry 
milk, followed by washing in Tris-buffered saline (TBS; 10 
mM Tris-HCl pH 8.0, 150 mM NaCl) containing 0.1% 
Tween20 (TBST). 
PULL-DOWN ASSAYS 
  BV173 cells were exposed to 1μM H2-GFP, TAT-GFP 
and MPH-2. After 3 hr, the cells were washed, trypsinized 
and lysed in E1a buffer. The cell lysates were clarified by 
centrifugation (10 min at 10.000g). An aliquot of total pro-
tein (1 g) was incubated with 10 L STREPtactin Matrix 
(IBA) overnight at 4° C. The mixture of sepharose and pro-
tein was washed 4 times with E1A buffer (150 mM, NaCl, 
5mM, HEPES 50 mM pH 7.0, EDTA 5mM pH 8.0, 1% Tri-
ton, NaVO4 2 mM and 1X protease inhibitor cocktail Roche, 
Mannheim, Germany). The bound protein was eluted with 
elution buffer (IBA), resolved by SDS-PAGE, and visualized 
by staining the blots with an -ABL antibody. 
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ANIMAL EXPERIMENTS 
  C57 BL/6N female mice (Harlan Winkelmann, Borchen, 
Germany) 6 to 8 weeks old were kept on sterile bedding in 
filter-top cages. They were provided with sterile food and 
water ad libitum. Peptides dissolved in PBS at a dosage of 
2.5 mg/kg were inoculated i.v. into recipient mice. Negative 
control mice received the same volume of phosphate-
buffered saline (PBS). Animals were sacrificed by CO2-
asphyxiation after 15 min, 2 hr, 6 hr, and 24 hr of treatment. 
Peripheral blood (PB) was obtained from the heart, and bone 
marrow (BM) was harvested from the femur and tibiae by 
flushing the bones with a syringe and 26-gauge needle. 
Spleen cells were isolated by passing the tissue through a 40 
M Nylon cell strainer (Beckton-Dickinson, Le Pont de 
Claix, France). For analysis of GFP expression, the MNCs 
were enriched using a Ficoll density gradient, and GFP ex-
pression was measured by fluorescence activated cells sort-
ing (FACS). 
RESULTS 
HIV-TAT-Fusion Peptides were Efficiently Delivered to 
Fibroblasts 
  To determine the most efficient peptide transduction sys-
tem, we compared the HIV-TAT with the Retro-HIV-TAT-
sequences fused to helix-2. We created fusion peptides con-
taining a Strep-tag (for efficient immunoprecipitation), HIV-
TAT or Retro-HIV-TAT as the peptide transduction tag, the 
helix-2 sequence, and GFP as reporter (Fig. 1A). A construct 
lacking the helix-2 sequence (TAT-GFP) was used as the 
control in experiments. These fusion peptides were ex-
pressed in the E.coli strain BL21, and purified by high affin-
ity chromatography (Fig. 1B). Peptide transduction was per-
formed in the presence/absence of chloroquine, which facili-
tates the up-take of membrane permeable peptides. Here, we 
show a higher efficiency of peptide transduction of helix-2 
upon fusion with the HIV-TAT (MPH-2), as compared to 
Retro-HIV-TAT in untransformed Rat-1 fibroblasts (Fig. 
1C). Due to its high efficiency, HIV-TAT was used as trans-
duction tag for the remaining studies. 
HIV-TAT MEDIATES THE EFFICIENT CELLULAR 
UPTAKE OF HELIX-2 FUSION PROTEINS 
  To confirm that the HIV-TAT fused membrane perme-
able helix-2 (now referred to as MPH-2) is able to enter leu-
kemic cells, we exposed Ph+ (Tom-1, BV173 and K562) and 
Ph- (Nalm-6) leukemic cells to the HIV-TAT-fusion pep-
tides. Peptides without the TAT-domain (H2-GFP), or TAT-
GFP were used as controls. The uptake rate was assessed by 
determining the percentage of GFP-positive cells by FACS. 
As reported in Fig. (2A), both the Ph+ and Ph- leukemic cell 
populations were nearly 100% positive for GFP in the pres-
ence of the transduction tag, whereas the cells incubated with 
control peptides were completely negative. Interestingly, the 
uptake of MPH-2 was more efficient than the TAT-GFP pep-
tide. To exclude that the GFP-positivity was due to peptides 
binding to the outer side of the cell membrane without pene-
trating the cell, we exposed Nalm-6 and BV-173 to H2-GFP, 
TAT-GFP or MPH-2, and performed immunoblots on cell 
lysates that excluded the membrane fraction. Both of the cell 
lines expressed the peptides corresponding to the HIV-TAT 
tag, which clearly confirmed greater uptake of MPH-2   
compared to the TAT-GFP control (Fig. 2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Recombinant membrane permeable peptides. A Sche-
matic representation of the fusion peptides used in this study with 
the indicated tags. B Recombinant peptides on a coomassie-stained 
SDS-PAGE Gel. C Peptide transduction efficiency with the indi-
cated peptide transduction tag fused to helix-2 in Rat-1 fibroblasts, 
provided as percentage of GFP-positive cells. The data represent 
the mean of 3 independent experiments with SD. 
  To determine the stability of MPH-2, Rat-1 fibroblasts 
were exposed to TAT-GFP, MPH-2 and H2-GFP for 3 hr. 
Then the cells were extensively washed, trypsinized, and 
seeded in fresh media. GFP expression was measured after 
30, 60 and 120 min, 6 hr and 24 hr. As depicted in Fig. (2C), 
GFP was detectable for at least 6 hr, showing that the TAT-
fusion peptides were stable for at least 6 hr.  
  Taken together, these data provide evidence that MPH-2 
transduces several different cell types with high efficiency, 
and remains stable for several hours. 
MPH-2 INTERACTS WITH BCR/ABL 
  To be therapeutically effective, MPH-2 has to inhibit the 
oligomerization of BCR/ABL by competing for the binding 
to the N-terminal CC-domain of BCR/ABL. We investigated 24    The Open Hematology Journal, 2011, Volume 5  Mian et al. 
whether MPH-2 could bind BCR/ABL. We exposed Ph+ 
BV173 cells to MPH-2, and to H2-GFP and TAT-GFP, 
which were negative controls. As shown in Fig. (1A), all of 
the recombinant peptides used in the experiments had a 
Strep-tag. Lysates were incubated with strep-tactin sepharose 
to pull down the strep-tagged peptides. Strep-tactin sepha-
rose-bound protein complexes were separated by SDS-
PAGE, and blotted on a methyl cellulose membrane, which 
was probed with an -ABL antibody. Here, we show that 
MPH-2 was able to precipitate BCR/ABL from the cell 
lysates, which confirms that MPH-2 and BCR/ABL directly 
interact Fig. (3). 
MPH-2 EFFICIENTLY REDUCES THE AUTOPHOS-
PHORYLATION OF BCR/ABL 
  The capacity of MPH-2 to interact with BCR/ABL in 
vivo prompted us to study its inhibitory effects on the aber-
rant BCR/ABL kinase-expressing cells. We investigated the 
autophosphorylation status of BCR/ABL at the phospho-
tyrosine residue Y245, which is critical for ABL-kinase   
activation
 in the Ph+ cell lines, Tom-1 (Ph+ ALL) and BV-
173 (lymphatic CML blast crisis), upon exposure to MPH-2. 
Tom-1 and BV-173 cells were transduced with MPH-2   
and TAT-GFP as negative controls. After 3 hr, cells were 
lysed, and a western blot was performed with antibodies   
directed against the c-ABL and phosphorylated ABL (Y245). 
As depicted in Fig. (4), in contrast to TAT-GFP, MPH-2 
inhibited the autophosphorylation of BCR/ABL, showing 
that MPH-2 targets BCR/ABL in patient derived Ph+ leuke-
mic cell lines. 
MPH-2 SELECTIVELY INHIBITS PH+ LEUKEMIC 
CELL LINES 
  To definitively establish the inhibitory effects of MPH-2 
on the transformation potential of BCR/ABL, we assessed 
the growth of human Ph+ patient derived cells. We exposed 
Tom-1, BV-173, and K562 (myeloid CML blast crisis), and 
the BCR/ABL negative Nalm-6 cells to 1 M of MPH-2, and 
the negative controls, TAT-GFP and helix-2-GFP. Cell vi-
ability was monitored by Trypan blue dye exclusion. As 
shown in Fig. (5A), the growth of Tom-1, BV-173 and K562 
were inhibited by MPH-2 in comparison to the controls, but 
MPH-2 did not exert any influence on the growth of Nalm-6 
cells. The inhibitory effects of MPH-2 on the growth of Ph+ 
leukemic cell lines were confirmed by XTT-proliferation 
assays. The human Ph+ cell lines Tom-1, BV-173, K562, 
and the Ph- cell line Nalm-6 were transduced with 1 μM of 
MPH-2, and the proliferation rate was measured after 48 hr 
of exposure. As depicted in Fig. (5B), the proliferation of 
Tom-1 and BV-173 BCR/ABL expressing cells was signifi-
cantly inhibited by MPH-2, whereas the proliferation of 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Uptake of HIV-TAT fusion peptides by leukemic cell lines and primary stem cells. A Ph+ cell lines; Tom-1 (Ph+ ALL), BV173 
(CML lymphatic blast crisis) and K562 (CML - myeloid blast crisis), and the Ph- Nalm-6 cells (ALL) were exposed to 1 M of the indicated 
peptides. GFP expression was determined using FACS. A one representative of 3 independent experiments is provided, as all yielded nearly 
identical results. B Intracellular uptake of MPH-2. Western blot analysis of the cell lysates cleared from the membrane fraction, and probed 
with an -GFP-antibody. C Stability of MPH-2. Rat-1 cells were exposed to 1 M of the indicated peptides. GFP expression was determined 
using FACS at indicated time points. 
 
 
 
 
 
Fig. (3). Interaction between MPH-2 and BCR/ABL. Pull-down 
of BCR/ABL from BV173 cells exposed to TAT fusion proteins. 
BV173 were exposed for 3 hr to 1 M of MPH-2 or the indicated 
control peptides. All fusion peptides harbored the Strep-tag (Figure 
1A) and were pulled down by the STREPtactin Matrix. They were 
analyzed for the presence of bound BCR/ABL by probing with the 
-ABL antibody. As a control, 10% of the inputs are shown. Targeting BCR/ABL by Competitive Peptides  The Open Hematology Journal, 2011, Volume 5    25 
K562 was only slightly reduced. No non-specific activity of 
MPH-2 on Nalm-6 cells was observed.  
  Taken together, these data indicate that MPH-2 specifi-
cally inhibits Ph+ human cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). MPH-2 inhibits the autophosphorylation of BCR/ABL. TOM-1 and BV173 cells were exposed for 3 hr to 1 M of MPH-2. 
Autophosphorylation was assessed by Western blotting with the -ABL and -p-ABL antibodies directed against whole and phophsorylated 
ABL, repsectively. 
 
 
 
 
 
 
 
 
 
Fig. (5). Growth inhibition of Ph+ leukemic cell lines upon exposure to MPH-2. Ph+ cell lines; Tom-1 (Ph+ ALL), BV173 (CML  
lymphatic blast crisis) and K562 (CML - myeloid blast crisis), and the Ph- Nalm-6 cells (ALL) were exposed to 1 M of the indicated  
peptides. A Proliferation was assessed by either the Trypan blue dye exclusion (A) or XTT (B) assay. 26    The Open Hematology Journal, 2011, Volume 5  Mian et al. 
TAT-FUSION PROTEIN ARE EFFICIENTLY   
DELIVERED IN VIVO 
  To investigate whether the MPH-2 is efficiently trans-
duced into primary cells we exposed primary Sca1
+/lin
- mur-
ine hematopoietic stem cells (HSCs) to MPH-2 for 3 hr. We 
found that these cells were transduced to a similar extent 
than the above described leukemic cell lines (Fig. 6A). To 
determine to what extent the TAT fusion peptides are ac-
tively transduced in vivo and to assess their in vivo stability, 
we inoculated i.v. 250 μg of TAT-GFP and MPH-2 peptides 
into recipient mice. MNCs from the peripheral blood and 
bone marrow and spleen cells were isolated after 15 min, 2 
hr, 6 hr and 24 hr of treatment. GFP expression was meas-
ured using FACS. As shown in Fig. (6B), the GFP expres-
sion level peaked at 15 min, was maintained until 6 hr, and 
was completely abolished after 24 hr in the peripheral blood 
and bone marrow cells. Consistent with peripheral blood, the 
GFP expression was maximal after 15 min and maintained 
until 24 hr in the bone marrow cells (Fig. 6B). In contrast, 
the spleen cells exhibited maximal GFP expression after   
6 hr of treatment, which was completely lost after 24 hr   
(Fig. 6B). Control mice had no detectable GFP expression  
in any organ.  
  In summary, these results demonstrate that TAT-fusion 
proteins are efficiently delivered to the hematopoietic organs 
and are pharmacologically stable for a pharmacologically 
reasonable period of time. 
DISCUSSION 
  The tetramerization and the formation of high molecular 
weight complexes are crucial for the leukemogenic potential 
of BCR/ABL, and inhibition of this process increases the 
sensitivity to the kinase inhibitor Imatinib [9]. The aim of the 
present study was to further develop the disruption of 
tetramerization as a therapeutic approach, by creating mem-
brane permeable inhibitory peptides and exploring their ef-
fectiveness in treating Ph+ leukemia. 
  We previously showed that the 39 a.a. sequence of the N-
terminal BCR coiled-coil region, representing the helix-2, 
binds to BCR/ABL when expressed using a retroviral trans-
duction system [13]. Here, we show that MPH-2, represent-
ing the helix-2, fused to a peptide transduction tag effec-
tively binds to BCR/ABL, which inhibits the aberrant kinase 
activity of BCR/ABL, and suppresses the growth of BCR/ 
ABL dependent leukemic cell lines.  
  In this study, we found that the MPH-2 administrated by 
i.v. injection efficiently transduced the MNCs in the periph-
eral blood, bone marrow and spleen, and was stabile for 
about 6 hr, which correlated with its in vitro stability.  
  The potential of the HIV-TAT as a peptide transduction 
tag was previously extensively explored using the model of 
TAT fused to -galactosidase. These studies showed that 
TAT fused -galactosidase is effectively delivered to many 
tissues, including the liver, kidney, heart, muscle, lung, 
spleen, and brain of mice by i.p. injection, and it fully main-
tains its biological activity [18,22]. 
  A complex formed by TAT and technetium 99 minutes 
after administering it by i.v. bolus in mice showed a rapid 
distribution throughout the body, with a gamma imaging 
pattern consistent with organ perfusion. The complex 
reached peak organ levels within 5 min after injection (liver 
> kidney > small intestine > lung > spleen > brain), and dis-
played modestly rapid blood clearance. Over the subsequent 
2 hr, the complex was cleared by both renal and hepatobil-
iary excretion, with activity appearing in the urinary bladder 
and bowel [23].  
  These findings along with our data strongly suggest that 
the TAT-delivered helix-2 peptide may provide the basis for 
a novel therapeutic approach to treat Ph+ leukemia. 
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Fig. (6). In vivo transduction of MPH-2. A Transduction efficiency in primary Sca1
+
/lin
-
 murine hematopoietic stem cells. B Transduction 
efficiency in vivo. 25 g/kg of body weight of MPH-2 were injected i.v., and after the indicated time points, 3 mice/group were sacrificed. 
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